Regeneron's Dupixent Takes Another Step Toward Blockbuster Status
Regeneron Pharmaceuticals (NASDAQ: REGN) unveiled phase 3 study data for its autoimmune disease drug Dupixent earlier this week that show it is effective in treating asthma. The success has management planning to file for Dupixent's approval in asthma patients soon, and that suggests Dupixent could win an OK next year. If so, then this drug could end up on the fast track to becoming a billion-dollar drug.
An estimated $50 billion annually is spent directly caring for asthma patients, and a lot of that money goes toward paying for costly hospital care for patients suffering an asthma attack.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Teva Pharmaceutical Industries Ltd ADR Aktie
31,50 €
0,32 %
Klare Kaufempfehlung: Teva Pharmaceutical Industries Ltd ADR erhält nur Buy-Einschätzungen.
Die Community prognostiziert für Teva Pharmaceutical Industries Ltd ADR ein Kursziel von 34 €, was einen leichten Anstieg gegenüber 31.5 € darstellt.
